Abstract Titles

Skip to Late-Breaking Abstracts »

All accepted abstracts will be available in the Journal for ImmunoTherapy of Cancer (JITC).

Abstract Titles

Onsite Posters

Onsite posters will be presented in the Poster Hall at the Walter E. Washington Convention Center in Washington, D.C. All odd numbered posters will be presented on Friday, Nov. 12, 2021. Even numbered posters will be presented Saturday, Nov. 13, 2021.

ePosters

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.


Search word or phrase:

# Type Title Authors Category Keywords
840 Poster Presentation A therapeutic humanized anti-carcinoma monoclonal antibody (mAb) can also identify immunosuppressive regulatory T (Tregs) cells and down regulate Treg-mediated immunosuppression Kwong Y. Tsang, PhD; Massimo Fantini, PhD; Christopher B. Cole, MD; Christina M. Annunziata, MD, PHD; Philip Arlen Novel Single-Agent Immunotherapies Antibody;Immune monitoring;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor antigens
841 Poster Presentation Targeting the intersection of immunology and redox biology: therapeutic potential of an anti-Thioredoxin antibody Gabriella Willman; Max Davidson; Carolina Trkulja; Owe Orwar; Sreesha P. Srinivasa, PhD Novel Single-Agent Immunotherapies Chemokine;Cytokine;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
842 Poster Presentation Exosome mediated reprogramming of tumor associated macrophages by exoASO-STAT6 for the treatment of Hepatocellular Carcinoma (HCC) Sushrut Kamerkar, PhD; Charan Leng; Kelvin Zhang, PhD; Olga Burenkova; Su Chul Jang, PhD; Samuel Kasera; Tong Zi; Kyriakos Economides, PhD; Timothy J. Soos; Dalia Burzyn, PhD; Sriram Sathyanaryanan, PhD Novel Single-Agent Immunotherapies Extracellular vesicles/exosomes;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
843 Poster Presentation Development and engineering of human sialidase for degradation of immunosuppressive sialoglycans to treat cancer Li Peng, PhD; Lizhi Cao; Sujata Nerle; Robert LeBlanc; Abhishek Das, Ph.D.; Sandip Shelke; Autumn Turner; Jenny Che; Zakir Siddiquee; Hui Xu; Lihui Xu, BS; Wayne Gatlin; James Broderick, M.D. Novel Single-Agent Immunotherapies Checkpoint blockade;Dendritic cell;Immune suppression;Immune tolerance;T cell;Tumor evasion
844 Poster Presentation A trispecific ROR1 x CD3 T cell engager mediates in vitro tumor cell killing and in vivo tumor eradication Bithi Chatterjee, PhD; Daniel Snell, PhD; Christian Hess, PhD; Matthias Brock, PhD; Fabio Spiga, PhD; Alexandre Simonin, PhD; Tea Gunde, PhD; Stefan Warmuth, PhD; Christopher Weinert, PhD; Nicole Bassler; Niels Kirk; Nina Schumacher; Dana Mahler; Yasemin Yaman; Bettina Bommer; Giorgio Gambino; Noreen Giezendanner; Benjamin Kuettner; Naomi Flueckiger; Robin Heiz; Sandro Wagen; Dania Diem; Julia Zeberer; David Urech, PhD Novel Single-Agent Immunotherapies Antibody;Bispecifics;T cell;Targeted therapy;Tumor antigens
845 Poster Presentation A colony stimulating factor 1 receptor-blocking bifunctional protein simultaneously targets tumor-associated macrophages and exhausted T cells for the treatment of triple-negative breast cancer Pandelakis Koni; Hung-Kai Chen; Yao-Wen Chang; Huey-Wen Hsiao; Chih-Lun Hsiao; Jing-Yi Huang; Ju-Pei Chen; Muh-Hwa Yang Novel Single-Agent Immunotherapies Antibody;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
846 Poster Presentation Pre-clinical validation of a FLT3L-fusion protein for dendritic cell expansion and anti-tumor efficacy Michelle R. Kuhne, PhD; Hamlet Chu; Sarah Ng; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nicholas Wilson, PhD Novel Single-Agent Immunotherapies Antigen presenting cells;Dendritic cell;Tumor infiltrating lymphocytes (TILs)
847 Poster Presentation Pharmacokinetics and pharmacodynamics of GS-3583 in cynomolgus monkeys Michelle R. Kuhne, PhD; Hamlet Chu; Christopher Clarke, PhD; Brian Carr; Manuel Baca, PhD; Magdeleine Hung; Mark R. Nagel; Alexandre Ambrogelly, PhD; Nishanathan Rajakumaraswamy Novel Single-Agent Immunotherapies Antibody;Antigen presenting cells;Dendritic cell
848 Poster Presentation Novel small molecule HPK1 inhibitor PCC-1 induces strong anti-tumor activity Sanjib Das, PhD; Sravan Mandadi, PhD; Jagmohan Saini, PhD; Sachin S. Chaudhari, PhD; Ameya Deshpande; Murugan Chinnapattu, PhD; Malini Bajpai, PhD; Priyanka Pangre; Varada Potdar; Megha Marathe; Pooja Sawant; Atul Akarte, PhD; Chandrasekhar Misra, PhD; Subhadip Das, PhD; Anuj Singh; Avratanu Das; Pandurang Lambade; Chaitanya Tirumalasetty; Raju Patole; Nilanjana Biswas, PhD; Vikas Karande; Heta Shah; Dayanidhi Behera; Nagaraj Gowda, PhD; Pravin S. Iyer, PhD Novel Single-Agent Immunotherapies Checkpoint blockade;Cytokine;Immune suppression;Solid tumors;T cell;Tumor microenvironment
849 Poster Presentation ReSTORE T cell engager platform depletes MDSC in parallel with antigen-specific solid tumor cytotoxicity Sterling C. Eckard, PhD; Bianca Rojo, PharmD; Li Mei; Alberto Ponce; Patrick Chun, MD; Victoria Smith, PhD Novel Single-Agent Immunotherapies Immune suppression;MDSC;Myeloid cells;Solid tumors;T cell;Targeted therapy;Tumor microenvironment
850 Poster Presentation Dual blockade of the EP2 and EP4 PGE2 receptors with TPST-1495 is an optimal approach for drugging the prostaglandin pathway Brian Francica, PhD; Justine Lopez; Anja Holtz; Dave Freund; Dingzhi Wang, PhD; Amanda Enstrom; Sam H. Whiting, MD, PhD; Chan C. Whiting, PhD; Thomas W. Dubensky, Jr., PhD Novel Single-Agent Immunotherapies Immune suppression;NK/NKT cell;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
851 Poster Presentation Harnessing innate immunity in cancer therapies: the example of Natural Killer Cell Engagers Olivier Demaria, PhD; Eric Vivier, PhD; Marie Vetizou, PhD; Audrey Blanchard Alvarez; Guillaume Habif, PhD; Cécile Bonnafous, PhD; Sivan Bokobza, PhD; Agnès Represa; Benjamin Rossi, PhD; Luciana Batista, PhD; Constance Vagne, PhD; Sabrina Carpentier; Stéphanie Cornen, PhD; Ariane Morel, PhD; Ivan Perrot, PhD; Yannis Morel, PhD; Laurent Gauthier, PhD Novel Single-Agent Immunotherapies Antibody;Bispecifics;Cytokine;NK/NKT cell;Targeted therapy;Tumor antigens;Tumor microenvironment
852 Poster Presentation Trifunctional NKp46/CD16a-NK cell engager targeting CD123 overcomes acute myeloid leukemia resistance to ADCC Laurent Gauthier, PhD; Angela Virone-Oddos; Jochen Beninga, PhD; Benjamin Rossi; Céline Nicolazzi; Céline Amara; Audrey Blanchard-Alvarez; Nicolas Gourdin; Jacqueline Courta; Alexandra Basset; Franceline Guillot; Gwendoline Grondin; Hélène Bonnevaux; Anne-Laure Bauchet; Ariane Morel, PhD; Yannis Morel, PhD; Marielle Chiron, PhD; Eric Vivier, PhD Novel Single-Agent Immunotherapies Antibody;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Targeted therapy;Tumor antigens
853 Poster Presentation ACTM-838: A microbial-based immunotherapy that delivers combination IL-15 + engineered STING to tumor-resident APCs After IV dosing in T-cell excluded solid tumors Haixing Kehoe, M.S.; Alexandre Iannello, PhD; Keith Cheung, PhD; Bret Peterson, PhD; Marie Marotel, PhD; Sara Tribble, B.S.; Hailey He, B.S.; Jonathan J. Hodgins, B.S.; Michele Ardolino, PhD; Christopher Rae, PhD; Christopher D. Thanos, PhD; Laura H. Glickman, PhD Novel Single-Agent Immunotherapies Antigen presenting cells;Cytokine;Immune adjuvant;Monocyte/Macrophage;Solid tumors;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
854 Poster Presentation SGN-B7H4V, a novel, investigational vedotin antibody-drug conjugate directed to the T cell checkpoint ligand B7-H4, shows promising activity in preclinical models Elizabeth Gray, PhD; Angela D. Epp; Michelle Ulrich, BS; Disha Sahetya; Kelly M. Hensley; Julie Hahn; Sean Allred; Jane Haass; Katie Snead; Sasha Lucas; John Gosink; Rogely Boyce; Esther Trueblood; Piper Treuting; Chris Frantz; Alyson J. Smith, PhD; Jason Schrum; Natalya Nazarenko; Shyra J. Gardai, PhD Novel Single-Agent Immunotherapies Antibody;Checkpoint blockade;Solid tumors;Targeted therapy;Tumor antigens
855 Poster Presentation Development of a Novel Anti-Multiple Myeloma Chimeric Antigen Receptor T Cell Therapy Chuck Hay, PhD; Mary Faber, PhD; Kemi Adeyanju, PhD; Jeffrey A. Medin, PhD Novel Single-Agent Immunotherapies Adoptive immunotherapy;Antibody;CAR T cells;Granulocyte;T cell;T cell lineages;Targeted therapy;Tumor antigens
856 Poster Presentation INBRX-106: A novel hexavalent anti-OX40 agonist for the treatment of solid tumors Emily Rowell, Ph.D.; Heather Kinkead, PhD; Elisabeth Torretti; Bryan R. Becklund, PhD; Florian J. Sulzmaier, PhD; William Crago; Kyle Jones; John C. Timmer, PhD; Quinn Deveraux, PhD; Brendan P. Eckelman, PhD; Analeah B. Heidt, PhD Novel Single-Agent Immunotherapies Costimulation;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
857 Poster Presentation SELECTIVE TREG DEPLETION IN SOLID TUMORS WITH ALD2510, A NOVEL HUMANIZED CD25-SPECIFIC, IL-2 SPARING MONOCLONAL ANTIBODY. Jemila Houacine; Anne Marie-Cardine; Aude Le Roy; Jérôme Giustiniani; Riad Abes; Anne-Sophie Chrétien; Stéphane Fattori; Laurent Gorvel; Armand Bensussan; Daniel Olive; Arnaud Foussat Novel Single-Agent Immunotherapies Antibody;Immune suppression;Immune tolerance;Regulatory T cell (Treg cell);T cell
858 Poster Presentation TILKine-2: A novel best-in-class tumor infiltrating lymphocyte (TIL) targeting engineered IL-2 with superior pre-clinical efficacy and safety for immunotherapy of cancer. Sreerupa Challa, PhD; Yao-Te Hsieh, PhD; Jonathan M. Carnino; Andrea Umana; Yuesheng Li; Jing Xu; Lingyun Rui Novel Single-Agent Immunotherapies Antibody;Bispecifics;Checkpoint blockade;NK/NKT cell;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
859 Poster Presentation Tuning the tumor microenvironment by reprogramming TREM1+ myeloid cells to unleash anti-tumor immunity in solid tumors Nadine Jahchan, PhD; Hanna Ramoth; Vladi Juric, PhD; Erin Mayes; Shilpa Mankikar; Ranna Mehta; Mikhail Binnewies, PhD; Subhadra Dash; Rachael Palmer; Joshua L. Pollack; Joshua Rudolph; Pamela Canaday; Linnea Haeggblom; Carlos Santamaria; xiaoyan Du, PhD; Leonard Reyno, MD; Kevin P. Baker, PhD; Linda Liang, PhD Novel Single-Agent Immunotherapies Antibody;Biomarkers;Checkpoint blockade;Cytokine;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors;Tumor microenvironment
860 Poster Presentation The anti-tumor activity of HSP-90 therapeutic cancer vaccine (AST-021p) combine with TLR2/3 agonist in a MMTV-neu transgenic model Jinho Kang; Eunkyo Joung, MD; Hunwoo Shin; Byung cheol Ahn; Eunjung Jung; Hun JH. Jung, MD./PhD.; Kyong Hwa Park Novel Single-Agent Immunotherapies Clinical study;Immune adjuvant;Immune monitoring;T cell;Targeted therapy;Tumor antigens;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor stroma;Vaccine
861 Poster Presentation Reprogramming regulatory T cells (Treg) using a MALT1 inhibitor for cancer therapy Peter Keller; Irina Mazo; Yun Gao; Vijayapal Reddy; Francisco Caballero; Sam Kazer; Amina Fu; Yi Sun; Dannah Miller; Roberto Gianani, MD, FCAP; James E. Marvin; Bret Stephens; Gregory L. Beatty, MD, PhD; Russell W. Jenkins; Ulrich Von Andrian, MD, PhD; Daniel Krappmann; Thorsten Mempel, MD, PhD Novel Single-Agent Immunotherapies Clinical study;Clinical trial;Cytokine;Immune tolerance;Regulatory T cell (Treg cell);Solid tumors;Tumor microenvironment
862 Poster Presentation Dectin-2, a novel target for tumor macrophage reprogramming in cancer immunotherapy Justin A. Kenkel, PhD; Po Y. Ho; Sameera Kongara, PhD; Karla A. Henning, PhD; Cindy L. Kreder; Jess L. Nolin; Steven J. Chapin, PhD; Marcin Kowanetz, Ph.D.; Michael N. Alonso, PhD; Shelley E. Ackerman; Edgar G. Engleman, MD; David Dornan, PhD Novel Single-Agent Immunotherapies Antibody;Antigen presenting cells;Dendritic cell;Immune adjuvant;Monocyte/Macrophage;Myeloid cells;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
863 Poster Presentation In vitro and in vivo studies establish DuoBody®-CD3xB7H4 as a novel drug candidate for the treatment of solid cancers Louise A. Koopman, PhD; Laura Smits-de Vries; Frederikke Lihme Egerod; Sebastiaan Wubben; Mischa Houtkamp, PhD; Stefanie A. De Poot; Madelon Paauwe; Edward van den Brink; Andrea Gorlani; Dennis Verzijl; Kate Sasser, PhD; Esther Breij, PhD Novel Single-Agent Immunotherapies Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor infiltrating lymphocytes (TILs)
864 Poster Presentation Identification of A Novel Allosteric Oral Cbl-b Inhibitor that Augmented T Cell Response and Enhanced NK Cell Killing in vitro and in vivo Jun Kuai, Ph D; Yingzhi Bi; Yilin Qi; Deborah G. Conrady; Rajiv G. Govindaraj; Graham Hone; R. Aldrin Denny; Ken Carson; Geraldine Harriman; Fang Wang Novel Single-Agent Immunotherapies Checkpoint blockade;Costimulation;Immune suppression;Immune tolerance;NK/NKT cell;T cell;Targeted therapy
865 Poster Presentation iosH2 exerts potent anti-tumor activity by blocking LILRB1/2 and KIR3DL1 receptor signaling Osiris Marroquin Belaunzaran, PhD; Anahita Rafiei; Anil Kumar; Marco Gualandi; Magdalena Westphal; Lorenz Vogt; Sean R. Smith; Michael A. Curran, PhD; Christoph Renner Novel Single-Agent Immunotherapies Checkpoint blockade;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors
866 Poster Presentation RBN-2397, a novel, potent, and selective PARP7 inhibitor, induces tumor-intrinsic Type I interferon responses and adaptive immunity in preclinical models and patient tumors Kristy G. Kuplast-Barr, Bachelor of Science; Melissa L. Johnson, MD; Manish R. Patel, MD; Timothy A. Yap, MD; Gerald S. Falchook, MD, MS; Patricia LoRusso; Ryan Abo, PhD; Chang Liu, PhD; Erika Manyak; Lisa Cleary; Viviana Bozon; Sudha Parasuraman, MD; Heike Keilhack; Kristen McEachern, PhD Novel Single-Agent Immunotherapies Biomarkers;Clinical study;Gene expression;Monocyte/Macrophage;Solid tumors;T cell;Targeted therapy;Tumor microenvironment;Tumor stroma
867 Poster Presentation TriTAC-XR is an extended-release T cell engager platform designed to minimize cytokine release syndrome by reducing Cmax in systemic circulation Kathryn S. Kwant, Ph.D.; Sony S. Rocha; Katrina Stephenson; Maria R. Dayao; Subramanian Thothathri; Rose Banzon; Wade H. Aaron, BS; Golzar Hemmati; Evan Callihan; Timothy Yu; Jessica O'Rear; Eric Bragg; Willis Kwong; Hubert Situ; Avneel Hundal; Stephen Yu; Taggra Jackson; Kevin J. Wright, Ph.D.; Yinghua Xiao, Master Degree; Linh To; Richard Austin, Ph.D.; Bryan Lemon, Ph.D.; Holger Wesche, Ph.D.; S. Jack Lin, Ph.D. Novel Single-Agent Immunotherapies Antibody;Immune toxicity;Solid tumors;T cell;Targeted therapy
868 Poster Presentation Overall survival on tebentafusp in metastatic uveal melanoma (mUM) across the range of tumor gp100 expression levels Emma Leach; Sarah Stanhope; Revashnee Naidoo; Shaad E. Abdullah; Laura Collins; Koustubh Ranade Novel Single-Agent Immunotherapies Bispecifics;Clinical trial;T cell;Tumor infiltrating lymphocytes (TILs)
869 Poster Presentation Locally administered immunotherapy self-delivering RNAi PH-762 results in abscopal clearance of untreated distal tumors, suggesting systemic immune response, in a murine hepatocarcinoma model Benjamin Cuiffo, PhD; Melissa Maxwell, MS; Dingxue Yan, PhD; Brianna Rivest, BS; James Cardia, PhD; Simon P. Fricker, PhD Novel Single-Agent Immunotherapies Checkpoint blockade;RNA;Solid tumors;Tumor microenvironment
870 Poster Presentation Targeting GCN2 kinase-driven stress response inactivation to restore tumor immunity in metastatic triple negative breast cancer Hariprasad Vankayalapati, Ph.D.; Kyle Medley, MS; Zhaoliang Li, PhD; Dongqing Yan, PhD; David Bearss, PhD; Alana Welm, PhD Novel Single-Agent Immunotherapies Biomarkers;MDSC;Myeloid cells;Solid tumors;T cell;T cell lineages;Targeted therapy;Tumor microenvironment
871 Poster Presentation Construction and Evaluation of Interleukin 3 (IL3)-Zetakine Redirected Cytolytic T Cells for the Treatment of CD123 Expressing Acute Myeloid Leukemia Rebecca Moeller, MSc; Julian Scherer, PhD; Sadik H. Kassim, PhD Novel Single-Agent Immunotherapies CAR T cells;Cytokine;Leukemia/Lymphoma;T cell;Targeted therapy;Tumor antigens
872 Poster Presentation PD1 x TGFbR2 and CD5 x TGFbR2 bispecifics selectively block TGFbR2 on target-positive T cells, promote T cell activation, and elicit an anti-tumor response in solid tumors Gregory L. Moore, PhD; Suzanne Schubbert, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Erik Pong, BS; Lukasz J. Ochyl, BS; Alex Nisthal, PhD; Seung Chu, PhD; James Ernst, PhD; John R. Desjarlais, PhD Novel Single-Agent Immunotherapies Antibody;Bispecifics;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)
873 Poster Presentation S-531011, a novel anti-human CCR8 antibody: anti-tumor responses through depletion of tumor-infiltrating CCR8-positive Tregs Ryohei Nagai, Ph.D.; Ryohei Nagai; Morio Nagira; Wataru Nogami; Michinari Hirata; Azumi Ueyama; Mai Yoshikawa, Ph.D.; Naganari Ohkura; Hisashi Wada; Yoji Nagira Novel Single-Agent Immunotherapies Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs)
874 Poster Presentation Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGFβ signaling, as novel single-agent immunotherapy Srinivas R. Boreddy, Ph. D; Reshmi Nair; Arindam Banerjee; Anshu Kuriakose; Prashant Kumar Pandey; Chaitali Dey; Meena Shri; Shruthi Rao; Bhadravathi Marigowda Shivakumar; Moni Abhram Kuriakose; Ram Bhupal Reddy; Amritha Suresh; Praveen Reddy Moole; Usha Bughani; Seng-Lai Tan, PhD; Pradip Nair Novel Single-Agent Immunotherapies Angiogenesis;Antibody;Bispecifics;Coinhibition;Cytokine;Immune suppression;Regulatory T cell (Treg cell);Solid tumors;Targeted therapy;Tumor microenvironment
875 Poster Presentation AL009, a fusion protein and multi-Siglec inhibitor, repolarizes suppressive myeloid cells and potentiates anti-cancer effects Sam Nalle, PhD; Helen Lam; Ling Leung; Spencer Liang; Daniel Maslyar, MD Novel Single-Agent Immunotherapies Checkpoint blockade;MDSC;Monocyte/Macrophage;Myeloid cells;Solid tumors
876 Poster Presentation Intratumoral administration and local retention of IL-2/IL-12 fusion proteins drive a potent systemic anti-tumor immune response Mehta K. Naveen, PhD; Bochong Li; Dane Wittrup; Patrick A. Baeuerle; Jennifer S. Michaelson Novel Single-Agent Immunotherapies Cytokine;Solid tumors;Tumor microenvironment
877 Poster Presentation PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth Phuong A. Nguyen, PhD; Jessica Ritter, PhD; Mohammad Zafari; Denise Manfra, PhD; Veronica Komoroski; Brian O'Nuallain, PhD; Ryan Phennicie; Kevin Kauffman, PhD; Dominika Nowakowska, PhD; Joe Wahle, PhD; Steve Sazinsky, PhD; Michael A. Brehm, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD Novel Single-Agent Immunotherapies Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
878 Poster Presentation Novel microbial immunotherapy approach for the treatment of bladder cancer Nicholas Glanville, PhD; Tobi Oke, BSc; Sonia Domingos-Pereira; Lenka Polak; Denise Nardelli-Haefliger, PhD; Livija Deban, PhD Novel Single-Agent Immunotherapies Dendritic cell;Monocyte/Macrophage;Myeloid cells;NK/NKT cell;Solid tumors;T cell;Targeted therapy
879 Poster Presentation A promising cancer immunotherapy target: Novel fully human agonist antibodies against the human T-cell costimulatory receptor CD27 Thierry Guillaudeux, PhD; Yulia Ovechkina; Shaarwari Sridhar; David Jurchen; David Peckham; Emily Frazier; Eric Tarcha, PhD; Shawn Iadonato, PhD Novel Single-Agent Immunotherapies Antibody;Costimulation;Cytokine;T cell;Targeted therapy;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
880 Poster Presentation Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis Sheena Pinto, PhD; Susanne Wingert, PhD; Jens Pahl, PhD; Armin Beez; Sabrina Purr; Uwe Reusch, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. Novel Single-Agent Immunotherapies Bispecifics;Monocyte/Macrophage;Solid tumors
881 Poster Presentation Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE®) in 3D spheroids Sheena Pinto, PhD; Savannah Jackson; Julia Knoch; Christian Breunig, PhD; Arndt Schottelius, MD, PhD; Joachim Koch, Prof. Novel Single-Agent Immunotherapies Bispecifics;Monocyte/Macrophage;Solid tumors
882 Poster Presentation Selective affinity-enhanced T cell receptor bispecific targeting of KRAS G12D neoantigen driven cancers Andrew D. Whale, PhD; Andrew Poole; Vijaykumar Karuppiah; Annabelle Hartt; Jaafar N. Haidar; Sylvie Moureau; Aimee Bence Lin; Marc Van der Kamp; Gregory D. Plowman; Annelise Vuidepot; David K. Cole; Chandramouli Chillakuri Novel Single-Agent Immunotherapies Bispecifics;Neoantigens;Solid tumors;T cell;Targeted therapy;Tumor antigens
883 Poster Presentation An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target human acute myeloid leukemia (AML) cell lines in vitro. Alessandra Romano, M.D., PhD; Nunziatina Parrinello; Sara Marino; Enrico La Spina1; Massimo Fantini, PhD; Philip Arlen; Kwong Tsang; Francesco Di Raimondo Novel Single-Agent Immunotherapies Antibody;Leukemia/Lymphoma;Myeloid cells;Regulatory T cell (Treg cell);Targeted therapy;Tumor antigens
884 Poster Presentation Engineered Toxin Body mediated depletion of TIGIT expressing immune cells for cancer immunotherapy Elizabeth Saputra; Garrett Cornelison; Jennifer Mitchell; Karia Williams; Andrea Mendiola; Rachael Orlandella; John Majercak; Joseph D. Dekker, Ph.D.; Chris B. Moore; Swati Khanna, Ph.D. Novel Single-Agent Immunotherapies Checkpoint blockade;Immune suppression;Regulatory T cell (Treg cell);T cell;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment
885 Oral Presentation Targeting FPR2 as a novel approach for immunotherapy in pancreatic cancer female patients – Studies of sexual immune dimorphism in the tumor microenvironment Dhifaf Sarhan, PhD; Fei D. He; Ahmed D. Calandigary; Enana Malki; Carlos Fernández Moro; Marina Kaisso; Peter Olofsson-Sahl; Marit Melssen; Matthias Löhr; Mikael Karlsson; Rainer Heuchel Novel Single-Agent Immunotherapies Immune suppression;Monocyte/Macrophage;T cell;Tumor microenvironment
886 Poster Presentation Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures Steve Sazinsky, PhD; Phuong A. Nguyen, PhD; Mohammad Zafari; Ryan Phennicie; Joe Wahle, PhD; Veronica Komoroski; Kathryn Rooney; Craig Mizzoni; Boris Klebanov; Denise Manfra, PhD; Jessica Ritter, PhD; Igor Feldman, PhD; Tatiana Novobrantseva, PhD Novel Single-Agent Immunotherapies Antibody;Antigen presenting cells;Immune suppression;MDSC;Monocyte/Macrophage;Myeloid cells;Tumor evasion;Tumor infiltrating lymphocytes (TILs);Tumor microenvironment;Tumor stroma
887 Poster Presentation Repolarization of T cells by AMV564 in patients progressing on checkpoint blockade Victoria Smith, PhD; Sterling C. Eckard, PhD; Bianca Rojo, MSc; Patrick Chun, MD Novel Single-Agent Immunotherapies Bispecifics;Clinical trial;Immune contexture;Immune monitoring;Immune suppression;MDSC;Myeloid cells;Regulatory T cell (Treg cell);T cell
888 Poster Presentation An integrative approach to optimize a synthetic EphA2/CD137 agonist: balancing potency, physiochemical properties, and pharmacokinetics to achieve robust anti-tumor activity Punit Upadhyaya, PhD; Gemma Mudd, .; Kristen Hurov; Johanna Lahdenranta; Elizabeth M. Repash, MSc; Julia Kristensson, .; Kevin McDonnell; Philip E. Brandish; Phil Jeffrey; Nicholas Keen Novel Single-Agent Immunotherapies Bispecifics;Costimulation;Solid tumors;T cell;Targeted therapy
889 Poster Presentation DuoBody®-CD3x5T4 induces efficient T-cell activation and killing of patient-derived head and neck cancer cells in vitro and ex vivo Rieneke van de Ven; Sonja H. Ganzevles, B.Sc; Myrthe Veth, B.sc; Patrick Franken; Esther Breij, PhD; Ruud H. Brakenhoff, Prof. dr.; Kristel Kemper, PhD Novel Single-Agent Immunotherapies Antibody;Biomarkers;Bispecifics;Cytokine;Solid tumors;T cell;Targeted therapy;Tumor antigens
890 Poster Presentation Manipulation of epithelial-to-mesenchymal transition reveals metastatic breast cancers support immune suppression via heme metabolism Michelle M. Williams, Ph.D.; Jessica L. Christenson, Ph.D.; Sabrina A. Hafeez, B.S.; Nicole S. Spoelstra, B.S.; Jill E. Slansky, PhD; Jennifer K. Richer, Ph.D. Novel Single-Agent Immunotherapies Immune suppression;Metabolism;Monocyte/Macrophage;Myeloid cells;Solid tumors;Targeted therapy;Tumor evasion;Tumor microenvironment
891 Poster Presentation S-531011, a novel anti-human CCR8 antibody: Antibody screening and evaluation of biological profiles Mai Yoshikawa, Ph.D.; Yoji Nagira; Morio Nagira; Tetsuya Yoshida; Shinpei Yoshida; Tetsuyoshi Soh; Hisashi Wada; Naganari Ohkura; Tatsuya Takahashi Novel Single-Agent Immunotherapies Antibody;Chemokine;Regulatory T cell (Treg cell);Targeted therapy;Tumor infiltrating lymphocytes (TILs)
892 Poster Presentation ABL503 (TJ-L14B), PD-L1x4-1BB bispecific antibody induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8+ T cells in tumor microenvironment Gihoon You, Ph.D.; Uijung Jung; Jaehyoung Jeon; Shinai Lee; Hyung-Seung Jin; Youngkwang Kim; Eunsil Sung, Ph.D.; Hyunjoo Kim, Ph.D.; Yangmi Lim, Ph.D.; Jonghwa Won, Ph.D.; Zhengyi Wang, PhD; Wenqing Jiang, PhD; Jaeho Jung, PhD Novel Single-Agent Immunotherapies Antibody;Biomarkers;Bispecifics;Checkpoint blockade;Costimulation;T cell
893 Poster Presentation ATG-101, a novel PD-L1/4-1BB bispecific antibody, augments anti-tumor immunity through immune checkpoint inhibition and PDL1-directed 4-1BB activation Hui Yuwen; Tengteng Li; Yijing Ren; Dirk Hoenemann; Jay Mei; Bo Shan; Bing Hou, Ph.D Novel Single-Agent Immunotherapies Bispecifics;Checkpoint blockade;Costimulation;NK/NKT cell;T cell;Tumor infiltrating lymphocytes (TILs)
894 Poster Presentation The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing Chiara Zambarda, PhD; Karolin Guldevall, PhD; Christian Breunig, PhD; Damien Toullec, PhD; Jacopo Fontana, PhD; Sheena Pinto, PhD; Jens Pahl, PhD; Susanne Wingert, PhD; Joachim Koch, Prof.; Björn Önfelt, Prof. Novel Single-Agent Immunotherapies Antibody;Antigen presenting cells;Bispecifics;Leukemia/Lymphoma;NK/NKT cell;Solid tumors;Tumor antigens
895 Poster Presentation Discovery of a safer 4-1BB agonist by targeting a membrane-proximal epitope combined with bispecific-mediated cross-bridging Andy Tsun, PhD; Tianhang Zhai; Xiaoniu Miao; Weifeng Huang; Chao Wang; Yifeng Xu; Zhijun Yuan; Tao Wang; Shuang Dai; Shaogang Peng; Tuling Pang; Wenchao Jiang; Yuhua Huang; Yuefeng Zou; Yingda Xu; Joanne Sun; Xinjiang Gong; Bin Li Novel Single-Agent Immunotherapies Antibody;Bispecifics;Checkpoint blockade;Immune toxicity;Solid tumors;T cell;Tumor infiltrating lymphocytes (TILs)